Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.37 |
| ▸ | HTR2B | P41595 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 8/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | SPAST | Q9UBP0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107718 | 1.00 | HTR2C (0.37) | HTR2CHTR2BHTR2ARORCSLC6A4 | |
| SCHEMBL103610 | 1.00 | HTR2C (0.37) | HTR2CHTR2BHTR2ARORCSLC6A4 | |
| SCHEMBL138524 | 0.87 | HTR1A (0.41) | RORCSLC6A4SLC6A2SLC6A3NR1I2 | |
| SCHEMBL138523 | 0.87 | HTR1A (0.41) | RORCSLC6A4SLC6A2SLC6A3NR1I2 | |
| SCHEMBL3598995 | 0.86 | SIGMAR1 (0.37) | HTR2CHTR2BRORCSLC6A4NR1I2 | |
| SCHEMBL3601264 | 0.86 | SIGMAR1 (0.37) | HTR2CHTR2BRORCSLC6A4NR1I2 | |
| SCHEMBL106665 | 0.86 | SIGMAR1 (0.37) | HTR2CHTR2BRORCSLC6A4NR1I2 | |
| SCHEMBL104569 | 0.86 | HTR2C (0.32) | HTR2CHTR2BHTR2AKCNH2 | |
| SCHEMBL104568 | 0.86 | HTR2C (0.32) | HTR2CHTR2BHTR2AKCNH2 | |
| SCHEMBL106649 | 0.79 | PDK1 (0.38) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426113-B1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | KOWA CO (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2426113-A1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | Kowa Company, Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | HTR2C 2623/4885HTR2B 2066/4885HTR2A 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.